

## Required Information for Colorado Prescription Drug Prescribers

<u>AstraZeneca Product</u>	<u>WAC Unit*</u>	<u>WAC Package*</u>	<u>Generic Drugs**</u>
LYNPARZA 100 mg	\$132.39 per TABLET	\$7,943.46 per 60 COUNT BOTTLE	None Available
LYNPARZA 150 mg	\$132.39 per TABLET	\$7,943.46 per 60 COUNT BOTTLE	None Available
LYNPARZA 150 mg	\$132.39 per TABLET	\$15,886.92 per 120 COUNT BOTTLE	None Available
LYNPARZA 100 mg	\$132.39 per TABLET	\$15,886.92 per 120 COUNT BOTTLE	None Available

AstraZeneca is providing you with Wholesale Acquisition Cost (WAC) information\* for its products and identifying generic products from the same therapeutic class in compliance with recent amendments to the Colorado Revised Statutes, specifically, CRS § 12-42.5-308. WAC does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price. Patients with health insurance that provides prescription drug coverage, may have a different out-of-pocket cost. For purposes of identifying “generic prescription drugs from the same therapeutic class”, the recent amendments define therapeutic class as “...a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.” AstraZeneca makes no representation or recommendation that the generic products listed herein are interchangeable or have the same efficacy or safety. Please refer to each generic product’s FDA-approved prescribing information for further information.

\*Wholesale Acquisition Cost (WAC) as published by FDB (an independent third party) represents the manufacturer’s published catalog or list price for a drug product to wholesalers as reported to FDB by the manufacturer. FDB does not perform any independent investigations or analysis of actual transaction prices for purposes of reporting WAC. For more information about First Databank’s drug pricing policy, visit <https://www.fdbhealth.com/drug-pricing-policy>.

\*\*The Uniform System of Classification (USC) schema was used to determine similar generic drugs. The CMS “Non-Innovator Multi-Source” indicator was used to determine the generic status of the drug products.

Source: AnalySource® 02/01/2023 as reprinted with permission by First Databank, Inc. All rights reserved.© 2023